Ask The Experts: Understanding and Preventing Clostridioides difficile Infection Recurrence
In this educational activity, experts discuss the mortality and morbidity that is a result of recurrent Clostridioides difficile infection (CDI) and development of CDI treatment plans that optimize the recurrence of infection. Future therapies in development that focus on preventing CDI recurrence will also be examined.
The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic. Time for additional questions from the webinar audience will be provided at the end of the presentation.
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to
- Define the mortality and morbidity associated with CDI recurrence.
- Develop a CDI treatment plan with the healthcare team that optimizes prevention of CDI recurrence.
- Assess novel therapies in development that focus on prevention of CDI recurrence.
Faculty
Kevin W. Garey, Pharm.D., M.S., FASHP, Activity Chair, Activity Chair
Professor and Chair
University of Houston College of Pharmacy
Houston, Texas
Pablo C. Okhuysen, M.D., FACP, FIDSA
Professor, Infectious Diseases
The University of Texas MD Anderson Cancer Center
Clinical Adjunct Professor
Baylor College of Medicine
Houston, Texas
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with Clostridioides difficile infection (CDI).
Format
This activity features slide presentations, active learning, and questions/discussion with faculty.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Kevin W. Garey, Pharm.D., M.S., FASHP
- Merck: Principal investigator
Pablo C. Okhuysen, M.D., FACP, FIDSA
- Summit Therapeutics: Principal Investigator
- Pfizer: Consultant
- Merck: Consultant
- Jaguar Health, Inc.: Consultant
- Singulex: Consultant
Process CE Within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to link to complete the evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #:
0204-000-20-402-H01-P
Release Date:
05/06/2020
Expiration Date:
05/06/2021
CE Credits:
1 hour/Application-based
Activity Fee:
Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.